FDA To Fast-Track Reviews Of Three Psychedelic Mental Health Drugs
The Food and Drug Administration said Saturday it will fast-track reviews of three psychedelic drugs for mental-health treatment, responding to a White House order to speed development and expand access.
The agency named MDMA, psilocybin and ibogaine as priorities and said it will coordinate with the Drug Enforcement Administration to speed review timelines and clear production bottlenecks. The move follows an April 18 White House executive order that directed federal agencies to ease restrictions and accelerate research of certain psychedelics.
The episode traces back to a burst of academic and commercial research in the late 2010s, when MDMA and psilocybin earned breakthrough-therapy status and phase 2 and phase 3 trials produced promising results. A 2023 phase 3 trial found MDMA-assisted therapy cut PTSD symptoms and improved functioning, and a 2022 phase 2 study showed a single 25 mg psilocybin dose reduced depression scores more than a subtherapeutic dose over three weeks. Regulators have not moved in a straight line: FDA rejected an MDMA-assisted therapy application in August 2024, citing weak evidence and safety and study-method concerns, which disappointed veterans groups and other advocates.
Mainstream reporting has shifted from cautious optimism to political urgency since last year's rejection, as influencers and some lawmakers pushed the issue and as the White House ordered rapid action. Federal scheduling still lists these drugs as having no accepted medical use, but recent DEA production quotas and market moves show the practical gap between that label and growing clinical demand; investors have already pushed psychedelic-related stocks higher even as analysts warn that early-stage trials carry big risks.
📊 Relevant Data
Psilocybin and MDMA are classified as Schedule I controlled substances by the DEA, meaning they are considered to have a high potential for abuse and no currently accepted medical use.
Drug Scheduling — Drug Enforcement Administration
In 2021, an estimated 8.3% of U.S. adults, or about 21 million people, experienced at least one major depressive episode.
Major Depression — National Institute of Mental Health
An estimated 3.6% of U.S. adults experience post-traumatic stress disorder in a given year.
Post-Traumatic Stress Disorder (PTSD) — National Institute of Mental Health
A 2022 phase 2 clinical trial found that a single 25 mg dose of psilocybin reduced depression scores significantly more than a 1 mg dose over a period of 3 weeks in patients with treatment-resistant depression, though with some adverse events like headache and nausea.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression — New England Journal of Medicine
A 2023 phase 3 clinical trial demonstrated that MDMA-assisted therapy significantly reduced PTSD symptoms and functional impairment compared to placebo in a diverse population with moderate to severe PTSD.
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial — Nature Medicine
📌 Key Facts
- FDA will fast-track reviews for three psychedelic drugs aimed at treating depression, PTSD and other mental health conditions.
- Two therapies are psilocybin-based and one is MDMA-based.
- The move follows a Trump executive order to accelerate research and ease some restrictions on these drugs.
📰 Source Timeline (1)
Follow how coverage of this story developed over time